| BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. [1] [2] [3] COPD patients may suffer episodes of exacerbation of symptoms (ECOPD) that contribute to poor health status, and increased healthcare costs. 4 The majority of ECOPD cases develop in response to infections 5, 6 and air pollution, 7 but the exact cause is not clear in up to 30% of cases. 8 In addition, other frequent clinical conditions may mimic the symptoms of ECOPD, including congestive heart failure, pneumonia, pneumothorax, pleural effusion, and pulmonary embolism (PE). 8 Previous studies suggest a high prevalence of PE in ECOPD. [9] [10] [11] [12] Tillie-Leblond et al evaluated PE in a series of 197 consecutive patients with ECOPD and found that the frequency of PE was 25%. 13 However, that study was performed in a highly selected subgroup of patients. In fact, a recent meta-analysis found a lower prevalence of PE of 16% in ECOPD compared with previous studies. 14 In patients with clinical suspicion of PE, there are some data suggesting that some PE diagnoses are less severe and these patients might not benefit from anticoagulation therapy. 15 Particularly for patients with ECOPD, some PE might be clinically unimportant, and the risk of submitting a patient with a clinically insignificant PE to anticoagulant treatment might outweigh the benefit. 16 Therefore, we designed the significance of puLmonary embolism in COPD exacerbations (SLICE) trial to assess the efficacy and safety of an active strategy for the diagnosis and treatment of PE compared to usual care (ie, standard care without any diagnostic test for diagnosing PE) in patients hospitalized because of ECOPD.
| METHODS
SLICE complies with the standard protocol items: recommendations for interventional trials statement. 17 
| Study hypothesis
This trial is designed to demonstrate the superiority of an active strategy for the diagnosis and treatment of PE compared to usual care in patients hospitalized because of ECOPD.
| Trial design and patient population
SLICE is an investigator-initiated, phase III, prospective, international, multicenter, randomized (1:1), open-label with blind end-point evaluation (PROBE), parallel-group trial (ClinicalTrials.gov identifier NCT02238639). Consecutive adult patients with ECOPD who require hospital admission are eligible for the study. The inclusion and exclusion criteria of the SLICE trial are listed in Table 1 ; the flow diagram is displayed in Figure 1 . The study information for all ineligible and eligible non-recruited participants will be retained in an anonymized form to provide detailed data on these patients in comparison to the study participant population. The study is being conducted in 16 centers in Spain and France.
| Randomization and trial interventions
In a patient with ECOPD who requires hospital admission, randomization should occur in the first 24 hours after admission. The trial uses a Inability to comply with study assessments computer-generated randomization scheme. Randomization is stratified by center and, within the centers, performed in blocks of 4 and 6 to ensure balanced distribution of the management groups. Randomization is performed centrally through the Internet (www.
estudioslice.org), and management allocation is concealed from all investigators. If the diagnosis of PE is confirmed, patients receive anticoagulant treatment according to guideline recommendations: parenteral anticoagulation (ie, unfractionated heparin, low-molecular-weight heparin, or fondaparinux) overlapped and followed by vitamin K antagonists; or parenteral anticoagulation followed by dabigatran or edoxaban; or monotherapy with apixaban or rivaroxaban. 18 
| Intervention group

| Control group
Patients in the control group undergo standard (ie, according to clinical practice guidelines) clinical management, 1, 8 as deemed appropriate by the attending physician.
| Study outcomes
The primary efficacy outcome is the composite of death from any cause, non-fatal (recurrent) symptomatic venous thromboembolism (VTE), or readmission for ECOPD within 90 days after enrollment.
Confirmation of (recurrent) symptomatic PE requires symptoms of PE and a new or an extension of a previous intraluminal-filling defect in (sub)segmental or more proximal branches on PE-protocol chest CTPA. Confirmation of (recurrent) symptomatic DVT requires symp- A central independent adjudication committee whose members are unaware of management allocation adjudicates all suspected study outcomes during the study period.
| Surveillance and follow-up
The study requires the following scheduled visits: enrollment, 1 week, 20 An estimated 355 participants will be needed in each trial group to detect a clinically important 10% absolute reduction in the primary outcome (ie, from 40% to 30%) with 80% power at 5% significance level. The 10% reduction was based on consultation with primary and secondary care colleagues (general practitioners and pulmonologists) who considered a 10% reduction to be small but clinically important. Since an interim analysis showed that 3% of patients were lost to follow-up, the Steering Committee anticipated a 5% loss to follow-up. This inflated each study group to 373 patients, giving 746 patients in total.
| Statistical analysis
All analyses will be performed on the intention-to-treat population, defined as all patients randomized, regardless of the management actually received. A per-protocol analysis, excluding protocol violations, will be performed as a sensitivity analysis. time-to-event data will be generated by the Kaplan-Meier method and compared using the log-rank test. Comparisons between the two groups will be performed using the Cox proportional hazard model. A P-value <0.05 will be considered statistically significant. All analyses will be performed with the use of the statistical programme SPSS V.24.0.
Subgroup analyses will include: age (<75 vs ≥75 years), sex (female vs male), COPD severity (FEV1 > 80%, 50% < FEV1 < 80%, 30% < FEV1 < 50%, and FEV1 < 30%), hospital volume (<300 beds vs ≥300 beds), and season of the year (autumn, winter, spring, and summer).
Two sensitivity analyses are planned for the primary outcome.
The first is an analysis of primary-outcome events after excluding those patients in the intervention group with a diagnosis of isolated sub-segmental PE. The second is an analysis of outcomes after excluding patients with a history of cancer.
| Study organization
The SLICE is an independent, investigator-initiated trial with an aca- 
| Study Committees
The structure of the SLICE study includes a Steering Committee, a central independent adjudication committee, and a DSMB.
The Steering Committee members have the final responsibility for the conduction of the study as well as the verification and analyses of all the study data. All the members of the Steering Committee have access to the study data, vouch for their accuracy, and completeness; they will contribute to the interpretation of the results, approve the final version of the manuscript verifying the fidelity of the article to the study protocol, and make the decision to submit the manuscript for publication.
| Adjudication committee
A central independent adjudication committee, whose members are unaware of management allocation, adjudicates all suspected outcome events (see Outcomes).
| Data and safety monitoring board
An independent DSMB periodically reviews the study outcomes with all information available concerning management allocation. The DSMB is composed of three expert clinicians with experience in the conduction and monitoring of clinical trials.
| Ethics and dissemination
The study is performed in accordance with the provisions of the Dec- 
| DISCUSSION
COPD patients may suffer from exacerbations, defined by an acute worsening of respiratory symptoms beyond normal day-to-day variations and leading to a change in medication. 8 Exacerbations are frequent (about one in four patients experience at least 2 exacerbations per year 21 ), and are major determinants of health status in COPD.
COPD exacerbations requiring hospital admission are independent predictors of mortality in COPD 22 and also drive disease progression, with approximately 25% of the lung function decline attributed to exacerbations. 23 The SLICE trial is currently enrolling patients to assess the efficacy and safety of an active strategy for the diagnosis and treatment of PE in patients with ECOPD. The trial has the potential to improve the management of exacerbations in patients with COPD. It is anticipated that the findings of this study will enhance our understanding of the exacerbations of COPD. This rigorously designed trial will address the role of PE in the decompensation of patients with COPD, potentially leading to better care.
Previous studies and meta-analyses have assessed the prevalence of PE in ECOPD. [9] [10] [11] [12] [13] [14] However, it is not known if all these PEs are clinically important. The broad use of CTPA for the diagnosis of PE has had minimal impact on the overall mortality related to PE, suggesting that some extra cases of PE may not have been clinically relevant. 24 To the best of our knowledge, this is the first randomized controlled trial that will determine the value of detecting PEs in patients with ECOPD. 26 Second, management of these outcomes may reduce the risk of reaching other endpoints (mainly death). Finally, some of readmissions for ECOPD might be caused by thromboembolic events. Thus, the Steering Committee felt justified in using a composite outcome that includes (recurrent) VTE and readmission for ECOPD. In addition, the components of the composite variable will be also analyzed separately.
In conclusion, the SLICE trial will provide high-quality evidence regarding the risks as well as the benefits of using CTPA in the evaluation of ECOPD.
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